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Abstraa Healthcare payers are faced with the need to allocate finite resources to maximize population health.To assist 
in decision-making, healthcare payers are increasingly using health outcomes information and economic analyses. 
Healthcare payers are often under pressure to make early decisions (around the time of product launch), when the 
evidence available is imperfect.They must also consider the equitable distribution of resources between therapeutic areas. 
Tools to help healthcare payers reach transparent and objective decisions include cost-utility analysis and decision 
modelling. In practice, healthcare payers in different countries (for example, Ireland, France and Canada) vary in the 
approaches taken to reimbursement and formulary listing decisionsThe key to decision-making among healthcare payers 
is the provision of appropriate evidence, comparing any new treatment approach to current best practice, in situations 
corresponding to real life. When data assumptions have to be made, these should be clearly stated with consideration of 
the impact of varying the assumptionsThe impact on budgets should also be considered. 
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INTRODUCTION 
Healthcare systems in the developed world are facing 
increasing demands, arising from aging populations, 
technological advances and increased patient 
expectations. As a result, governments and healthcare 
payers are faced with the need to allocate limited 
resources for maximum benefit (1,2). To assist in 
decision-making, healthcare payers are increasingly using 
health outcomes information and economic analyses. 
This paper aims to describe some of the difficulties faced 
by healthcare decision-makers and some tools being 
used to overcome these problems, and briefly 
summarizes examples of the way healthcare payers make 
decisions in different healthcare systems. 
DIFFICULTIES tN HEALTHCARE 
PAYER DECISION-MAKING 
Healthcare payers are charged with the responsibility to 
reach a decision on whether or not to fund particular 
therapeutic approaches, based on balancing the costs and 
benefits of the therapy. If it is clear that when a treatment 
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costs more than alternatives while delivering fewer 
benefits (and/or more harms), the decision not to fund 
the treatment can be easily made.There is also a minority 
of cases where the therapy can be clearly shown to cost 
less than alternative approaches while generating more 
benefits - in these cases, it could be expected that 
healthcare payers should also have few problems with 
making the decision to fund the treatment. 
More commonly, healthcare payers have to decide 
whether or not to recommend treatments that either 
cost less and deliver fewer benefits than alternatives, or 
cost more but deliver greater benefits than previous 
therapies. In such cases, wider issues of budget impact 
must also be considered. Decisions have to be taken on 
whether the extra resources required can be obtained 
by cutting back elsewhere, so that total benefits from a 
relatively fixed budget can be increased, or if additional 
funds can be found. 
A further difficulty faced by decision makers 
considering the introduction of a product with clear 
clinical benefits over alternative treatments is the 
potential impact on prescriber behaviour and patient 
expectations. Even if the product represents good value 
for money, increased demand may result in considerable 
impact on budgets. For example, when the highly 
selective serotonin reuptake inhibitors were developed 
for the treatment of depression, they were shown to be 
at least as cost-effective as traditional treatment with 
tricyclic antidepressantsThe expectation was that there 
would not be a dramatic increase in prescribing costsYet 
greater demand for effective treatments that had 
relatively few side-effects led to an exponential increase 
in prescribing costs (3). 
Healthcare payers are under pressure to make an early 
decision on funding status to ensure that new treatments 
become available promptly. Partly as a consequence of 
this time pressure, the evidence on which the decision 
must be based will often be imperfect. For example, 
there may be problems with the quality of the evidence 
available, which, in the case of pharmaceuticals, 
commonly comes from randomized controlled clinical 
trials that, early in product development, tend to be 
restrictive in patient population and of small scale. 
Furthermore, the focus of the evidence may be geared 
towards the need for regulatory approval, failing to 
address the specific needs of healthcare payers (4). 
Common difficulties with the evidence, from the health- 
care payer perspective, include inappropriate comparisons, 
use of intermediate outcomes, inadequate duration of 
follow-up and lack of data on resource use and economic 
impact.These problems were highlighted in a review of 
industry submissions to the agency considering 
reimbursement in Australia (5). Of 326 submissions 
between 1994 and 1997, 2 I8 (67%) had a total of 249 
significant problems, with the majority of these (62%) 
related to estimates of comparative efficacy In a review 
of 2 I submissions to a Canadian reimbursement agency, 
only five submissions were judged to have complied with 
the guidance given on evidence required (6). 
Early technology assessment carries the risk that 
inappropriate decisions will be made - a treatment that 
is truly clinically ineffective or cost-ineffective could be 
recommended for use in practice (with subsequent 
difficulties in removing it from the armamentarium), or a 
treatment that is truly clinically effective or cost-effective 
could fail to be recommended (with potentially adverse 
consequences for patients). Furthermore, in addition to 
costs and benefits, healthcare payers must take into 
account other issues, such as impact on specific sub- 
groups of patients. There is also a need to balance 
equitable resource use across different disease or 
therapeutic areas.And underlying all the difficulties facing 
healthcare payers is the need to ensure that decisions 
are taken in a fair and transparent manner. 
In seeking to address the difficulties that healthcare 
payers face when making decisions, a number of tools 
have been developed. Healthcare payers are making 
increasing use of cost-utility analysis, to assist in the 
efficient allocation of resources across therapeutic areas. 
To address the difficulties inherent in early technology 
assessment, most decision-making bodies are willing to 
recommend the collection of more evidence, particularly 
in subgroups of patients who are most likely to benefit 
from treatment, with revisiting of the funding decision in 
the light of the new evidence. Healthcare payers are also 
seeking to address shortcomings in evidence by using 
modelling to synthesize data from a range of sources 
including explicit judgements by experts. Such an 
approach also makes explicit assumptions, thereby 
facilitating transparency of decision-making.The tools of 
cost-utility analysis and decision-modelling are 
considered in more detail below. 
COST-UTILITY ANALYSIS 
Healthcare payers deciding on the efficient allocation of 
resources need to be able to consider both 
improvements in quality of life gained by a treatment, and 
the impact on duration of life, as well as the cost 
required to achieve these gains. This requires 
considerable synthesis of information into a single scale, 
so that direct comparisons can be made across 
therapeutic areas. The scale often used by healthcare 
payers is the cost per quality-adjusted life year (QALY) 
gained. The following is a brief description of the 
calculation of cost per QALY gained. 
Measuring utility 
The first stage in calculating cost per QALY is to assess 
the quality of different health statesThis is expressed in 
terms of the utility, that is, the desirability of different 
health states. Utility is measured by asking patients or a 
wider population to state their views on different health 
states. One method of collecting these views that is 
gaining increasing favour is the use of questionnaires 
(such as the Health Utilities Index (7) and the EQ-SD 
(8)) that ask about different attributes of health. The 
attributes assessed by the EQ-SD are shown in Table I. 
A total of 245 different health states can be defined using 
the EQ-SD (i.e. 3s for the three possible answers in five 
attributes, plus the health states of unconscious and 
dead). Each of these health states is then assigned a value 
on a scale of 0 (death) to I (perfect health), obtained by 
asking the opinion of a wide sample of the general public. 
In the U.K., the sample consisted of 3395 members of 
the public (9). For example, the mean value assigned to 
the health state consisting of some problems in walking 
about, but no problems with self-care or performing 
usual activities and no pain/discomfort or anxiety/ 
depression was 0.85, while a mean value of 0.52 was 
assigned to the health state consisting of some problems 
with walking about, self-care and usual activities, with 
moderate pain/discomfort and moderate anxiety/ 
depression. 
Quality-adjusted life years 
Once the utility value placed on a patient’s health is 
obtained, the time spent at each utility value can be 
assessed, as shown diagrammatically in Fig. I, so that the 
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FIGURE I. Calculation of quality-adjusted life-years with and without a hypothetical treatment. 
number of QALYs can be calculated by multiplying each 
utility value by the time spent at that value, and summing 
all the individual elements over the time period. This 
figure also shows the time at each utility value if a 
hypothetical treatment is given.The number of QALYs 
gained by the treatment is the difference between the 
QALYs with and without the therapy. 
Cost per QALY 
Alongside assessments of QALYs, costs can be taken into 
account.These usually include the cost of the treatment 
itself and the alternative form of management, together 
with other relevant healthcare costs, such as the cost of 
consultations, management of any adverse events from 
treatment and costs arising from treatment failure. 
Using cost-utility analysis in decision- 
making 
Once a cost-utility analysis has been carried out, 
healthcare payers can compare the value of the therapy, 
in terms of its extra cost per additional QALY, with 
treatments in other disease areas.This allows a threshold 
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to be used, either implicitly or explicitly, below which 
treatments may be funded. In the U.K., for example, 
although no explicitly stated threshold for cost per 
QALY of treatments deemed economically acceptable 
has been published, analysis of I9 recent decisions taken 
by the National Institute for Clinical Excellence (NICE) 
showed that only around half cited a cost per QALY (I 0). 
Of these, positive recommendations were given to all but 
one treatment with a cost per QALY below f30 000, 
partly achieved by restricting use to those patients 
experiencing greatest benefits from treatment.Treatment 
with riluzole for a subgroup of patients with motor 
neuron disease was recommended, despite the cost per 
QALY of f34 OOO-f44 000, because of the severity of 
impairment of patients and short survival time. Other 
treatments with a high cost per QALY (f40 OOO-f90 000) 
were not recommended. In the U.S.A., an implicit 
threshold of $50 000 per QALY has been observed. 
DECISION MODELLING 
Medical practice involves making hundreds of decisions 
each day. Evidence comparing alternative treatment 
approaches obtained from trials, systematic reviews and 
meta-analyses, together with hidden values and assump- 
tions derived from their training and experience, allow 
clinicians to arrive empirically and intuitively at decisions, 
which, hopefully, are appropriate in the majority of cases. 
Developments, such as the use of evidence to devise 
treatment protocols and management guidelines, seek to 
reduce inappropriate decision-making by collating and 
weighting information from a variety of sources. 
In the more recent field of healthcare management, 
such guidelines that draw together multiple sources of 
evidence are not always available. Furthermore, informal 
synthesis of information can lead to lack of support from 
key stakeholders and distrust of the decision taken. 
Consequently, there is a need to ensure that decisions 
having potentially far-reaching implications for patients, 
healthcare professionals, manufacturers and politicians 
alike (such as a recommendation to use or not use a 
particular medication) should be taken explicitly and on 
the basis of a clear and rational framework. Such an 
Information reqiured 
explicit framework is provided by decision modelling, 
which also attempts to address the difficulties inherent in 
making decisions under conditions of uncertainty and 
where complete data is not available. 
What is a decision model? 
A decision model is a mathematical prediction of health- 
related events, each of which are linked to costs and 
health outcomes. It usually compares mutually exclusive 
interventions for a specific patient group, synthesizing 
data from various sources. Where data is incomplete, 
explicit assumptions are made, and the impact of changes 
in these assumptions can be investigated so that 
assessment of uncertainty can be made. Decision models 
used by healthcare payers synthesize economic and 
clinical outcomes to answer appropriate questions 
(Fig. 2). Such models are not alternatives to clinical trial 
data - rather they are a tool to make explicit the factors 
that are being considered in a decision, rather than 
allowing these factors to be considered implicitly (Fig. 3). 
This approach allows discussion of the unknown 
parameters and agreement on the assumptions to make. 
before seeing the associated outcomes, thereby aiding 
discussion and debate among decision-makers. Such an 
approach gives an objective framework to a decision. 
Recently, the International Society for Pharmaceutical 
Outcomes Research (ISPOR) published the principles of 
good practice for decision analytic modelling in health 
care evaluation (I I). These principles emphasized the 
need for validation of models internally (to calibrate the 
model and ensure there are no bugs hampering their 
use), between models (to ensure results are consistent 
with other approaches) and externally (to make 
predictions). Methodolgical guidelines on decision 
modelling were also published following a consensus 
conference on economic modelling in health technology 
assessment, held in England in I999 (I 2). 
Using decision modelling 
Decision models have been used to assess cost- 
effectiveness, without restriction to those issues that are 
Decision reqiured 
Extrapolatrng beyond trial follow-up 
Maklng results appropriate to a specific setting 
Attaching “nit costs to resource use 
Mappmg lrom condlton.speclflc wtcome~ to QALYs 
FIGURE 2. Synthesis of information in respiratory disease reqwed in healthcare payer 
DECISION-MAKING BY HEALTHCARE PAYERS 535 
Questions arislng from an incomplete data set 
What does a 20% reduction in exacerbations 
mean for symptom-free days and QALYs? 
How do sddti!onal exacerbations translate into 
resource “se and costs? 
How should these trial data over 30 weeks be 
interpreted over 5 years or more? 
How do these trial results apply to standard 
practice in our country/centre? 
Hidden values and assumpt,ons 
FIGURE 3. Implicit and explicit decision-making. 
Fscihtstes sccountablhty 
Effect of varying assumptions can 
measured in clinical trials, so that all ways that patients 
could be managed are included. For example, in the field 
of respiratory care, a decision model has been developed 
to assess the cost-effectiveness of alternative asthma 
management strategies (I3).This model is based on the 
probability of moving between different health states, 
each of which is associated with a specific cost. The 
transition probabilities are determined, where possible, 
from clinical trials and other evidence -where evidence 
is lacking, explicit assumptions are made that can be 
altered to test the impact. 
The overall impact of a treatment on transition through 
the health states over a specified time period can be tested, 
with the results presented on a cost-effectiveness plane 
(Fig. 4). Estimates are repeated to reflect the uncertainty in 
parameters, with the clustering of points giving an 
indication of confidence in the findings. For example, the 
model of asthma management strategies showed that 
Seretide was comparable in cost to the comparative 
management approach, while resulting in improved health 
outcomes (Fig. 5) (I 3). Results can also be presented as a 
cost-effectiveness acceptability curve, whereby the 
probability of a treatment being cost-effective is plotted 
against varying amounts that the decision maker may be 
willing to pay for an additional unit of health outcome. 
In chronic obstructive pulmonary disease (COPD), 
work is underway to develop appropriate models to aid 
decision-making, though this is hampered by the lack of 
agreement on a clear way of defining the natural history 
of the condition. 
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FIGURE 5. A decision model of asthma management showed that treatment with Seretlde (salmeteroI/flutlcasone proplonate) was 
similar In cost to comparative therapy (formoterolibudesonlde) but more effective ( 13). 
DECISION-MAKING IN PRACTICE 
Having discussed some of the 
healthcare payers when making 
difficulties faced by 
decisions about the 
equitable distribution of resources between therapies 
and management approaches, and considered two of the 
tools being used, this section of the paper briefly 
summarizes healthcare payer decision-making in 
practice, focussing on reimbursement and formulary 
listing in Ireland, France and Canada. 
Drug reimbursement in Ireland 
In Ireland, as in other developed countries, there has 
been a rapid increase in public expenditure on pharma- 
ceuticals in recent years - rising from +Z227 million in 
1993 to JZ53 I million in 2000 (14,15). Drugs having the 
highest impact on the budget (that is, acquisition cost 
multiplied by the volume) include a number of products 
used for the treatment of respiratory conditions. 
Overall, I I% of pharmaceutical expenditure is for 
respiratory products (14). There are I I different 
schemes covering pharmaceutical reimbursement in 
Ireland, with the majority of patients (57.3%) registered 
as being eligible to benefit under one of the General 
Medical Services schemes (I 6,I7). Although prescrip- 
tions are free for those on low incomes and for the 
elderly, there is co-payment for other patients. Patients 
with some chronic diseases (though not asthma or 
COPD) receive free prescriptions. Pricing of pharma- 
ceutical products varies with the reimbursement 
scheme, but generally includes the manufacturers price 
with the addition of a wholesale margin (I 7.47%) and a 
dispensing fee (e2.3 l-2.65). In some schemes, a retail 
margin (50%) is also added. For the most expensive 
medications, the retail margin and dispensing fees are 
replaced with a monthly patient care fee of e43.93 ( 16). 
In an attempt to control expenditure, an indicative drug 
target scheme has been introduced, which aims to reduce 
the level of prescribing without adversely affecting the 
quality of care by promoting therapeutic and generic 
substitution, and cost-effective prescribing, while 
discouraging prescribing of drugs with limited clinical 
efficacy (I 8). Each general practitioner is given a target for 
expenditure, based on the age and gender of the practice 
population, and a proportion of any savings made can be 
retained by the practice for service development. Part of 
the budget is allocated to expenditure on budget neutral 
products (e.g. statins, nicotine replacement therapy). 
There are also some restrictions on volume of 
treatments (e.g. sildenafil) that can be prescribed, while 
other products are restricted to use by consultants. 
In Ireland, the price of new products is linked to the 
lesser of the U.K. price and the average price of the same 
product in a basket of European countries (Denmark, 
France, Germany, Netherlands and U.K.), and once the 
price is agreed, it remains fixed and is only very rarely 
renegotiated (19). There is no direct barrier to 
reimbursement in Ireland. However, since August 1997, 
the Department of Health has reserved the right to seek 
cost-benefit studies for any new chemical entity 
introduced to Ireland (20). Such economic analyses are 
evaluated by the National Pharmacoeconomic Centre. 
which also conducts research into high cost therapeutic 
areas and is involved in education to advance the 
understanding of pharmacoeconomics in Ireland (21). 
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The centre has developed health technology 
assessment guidelines, similar to those in use by the 
National Institute for Clinical Excellence in England and 
Wales (22).The guidelines are user-friendly and flexible, 
providing an opportunity for industry to present and 
discuss the economic data available. A pragmatic 
approach is taken to health technology assessment, with 
decision-makers accepting that studies may not have 
been conducted in Ireland - there is concern that 
insisting on national studies could discourage manu- 
facturers from introducing innovative products into the 
small Irish market. Although pharmacoeconomic evalua- 
tion has not taken a major role in decisions about 
reimbursement and formulary listing in Ireland, this is 
likely to change in the future. 
Reimbursement in France 
The reimbursement system in France changed 2years 
ago. Now, there has to be explicit demonstration of the 
benefits of new drugs to justify reimbursement (2). 
Reimbursement of products is at varying rates - for 
example, drugs for HIV infection and cancer receive 
100% reimbursement, while those for asthma are 
reimbursed at 65% and those showing only limited 
benefits are reimbursed at 35%. However, the majority of 
patients have health insurance to cover co-payment of 
drugs, so patients are not directly affected by the financial 
consequences of reimbursement decisions. 
Formulary access in Ontario, Canada 
In Canada, the provincial government of Ontario spends 
approximately Can$l-5 billion each year on pharma- 
ceutical services for the elderly and for patients receiving 
social assistance (in total, amounting to 35% of the 
Ontario population). The provincial government has a 
responsibility to ensure that the budget is spent as 
efficiently as possible. When a pharmaceutical company 
wishes to launch a new product in Canada, they must 
first receive federal regulatory approval, before being 
assessed by the Patented Medicines Price Review Board. 
The latter sets the maximum Canadian price permitted, 
based on a median price derived from the U.S.A. and a 
basket of European countries. 
The provincial drugs and therapeutics committee 
advises the provincial government whether or not it 
should pay for the drug for the beneficiaries of the 
province’s drug programme.The committee consists of a 
chair and I I members, each of whom can serve a 
maximum of 6 years, consecutively. Former members 
often serve as consultants to the committee. Manu- 
facturers prepare submissions of clinical and economic 
data, for review by the committee. The key clinical 
evidence considered by the committee are the outcomes 
achieved with the therapy, with laboratory measures (e.g. 
FEV,) having least influence, and progressively more 
influence from signs and symptoms, health-related quality 
of life (QALY) and survival. In ideal circumstances, at the 
top of the hierarchy of evidence is the impact on quality 
adjusted life years, as this measure captures both quality 
and quantity of life. However, this can be undermined if 
the committee is unable to trust the methods used to 
calculate the QALYs. Costs are considered from the 
perspective of the drug budget, the healthcare system 
(i.e. the Ministry of Health) and society. However, in 
reality, the societal perspective is given less weight as the 
recommendations are intended for use by the provincial 
Minister of Health. In addition to the efficacy and safety 
outcomes, and relevant costs and savings, the 
comparison used in the evidence has considerable 
impact on the recommended decision. Any new treat- 
ment must be compared with the therapy it is likely to 
replace. If not, reimbursement is unlikely to be 
considered until such evidence is available. Utilization 
potential is also important - that is, how the product is 
likely to be used in practice. The committee will then 
decide to give full listing on the provincial formulary, 
restricted listing or exclude the product from the 
formulary. In the last decade, there has been a reduction 
in the proportion of products given full listing, while 
many products have received listing for limited 
circumstances only.This trend is expected to continue in 
the future. 
WHY CAN DEMONSTRATlON OF 
GOODVALUE FAILTO INFLUENCE 
HEALTHCARE PAYERS? 
In all the healthcare systems considered, as elsewhere in 
the developed world, the presentation of health 
outcomes information and pharmacoeconomic analyses 
demonstrating the value of a new product does not 
guarantee decision-making in f&our of the product. 
There are a number of possible reasons. 
The wrong comparator has been used - possibly 
because trials have been designed for regulatory 
approval, involving comparison with placebo rather 
than customary care. 
Evidence is not representative of real use - as 
discussed in the previous paper by Mapel & Pearson, 
clinical trials may fail to include the populations of 
interest to healthcare payers, restricting the value of 
the data. 
Lack of precision - if there are too many assumptions, or 
these are not explicitly declared and able to be varied, 
decision-makers can lose confidence in the findings. 
Cost impact and lack of affordability - interestingly, this 
is probably not a common reason for rejection as the 
general aim of healthcare payers is not usually to 
reduce the budget, rather it is to ensure that the 
budget is spent wisely. 
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?? Formulary access may be restricted to prevent 
physicians from prescribing the drug in circumstances 
where the value of the product is low. 
CONCLUSIONS 
In conclusion, healthcare payers are faced with the need 
to allocate finite resources in order to maximize 
population health.To assist in decision-making, healthcare 
payers are increasingly using health outcomes informa- 
tion and economic analyses. However, there is pressure 
to decide on funding status before or as soon as the 
product is marketed, though this may mean that there is 
limited evidence on which to base the decision. 
Furthermore, healthcare payers have to balance the 
needs of all therapeutic areas. To assist decision-making, 
tools that have been developed include cost-utility 
analysis, which considers costs, quality of life and quantity 
of life (QALYs), and decision modelling. Decision-makers 
may also use cost-effectiveness analysis to focus the 
availability of drugs to patient subgroups or patient 
indications where the cost-effectiveness is shown to be 
most favourable. The key to decision-making among 
healthcare payers is the provision of appropriate 
evidence, comparing any new treatment approach to 
current standard practice, in situations corresponding to 
real life. When assumptions have to be made, these 
should be clearly stated with consideration of the impact 
of varying the assumptions. The impact on budgets 
should also be considered. 
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